Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “DTC - Differentiated Thyroid Cancer”

173 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 173 results

Large-scale testing (Phase 3)Not Yet RecruitingNCT07239674
What this trial is testing

Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC

Who this might be right for
Intermediate-to-High Risk Differentiated Thyroid Cancer
West China Hospital 646
Testing effectiveness (Phase 2)Study completedNCT02973997
What this trial is testing

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Who this might be right for
Columnar Cell Variant Thyroid Gland Papillary CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaMetastatic Thyroid Gland Follicular Carcinoma+23 more
Academic and Community Cancer Research United 57
Testing effectiveness (Phase 2)Study completedNCT01013597
What this trial is testing

Trial of LBH589 in Metastatic Thyroid Cancer

Who this might be right for
Thyroid Carcinoma
University of Wisconsin, Madison 13
Large-scale testing (Phase 3)Active Not RecruitingNCT03570021
What this trial is testing

ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer

Who this might be right for
Thyroid Cancer
Gustave Roussy, Cancer Campus, Grand Paris 352
Testing effectiveness (Phase 2)UnknownNCT04952493
What this trial is testing

Anlotinib or Penpulimab in Combination With RAI for DTC

Who this might be right for
Thyroid Cancer
Peking Union Medical College Hospital 42
Testing effectiveness (Phase 2)Study completedNCT02702388
What this trial is testing

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

Who this might be right for
Thyroid Cancer
Eisai Inc. 241
Very early researchLooking for participantsNCT06898437
What this trial is testing

Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Radioiodine Refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital 20
Not applicableUnknownNCT05510934
What this trial is testing

Shared Care Thyroid Cancer Follow-up Utilizing Thyroid Cancer Assessment Reminder System (TCARS) Study - A Pilot Study.

Who this might be right for
Low Risk Differentiated Thyroid Cancer
Nova Scotia Health Authority 60
Testing effectiveness (Phase 2)Looking for participantsNCT06970353
What this trial is testing

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Who this might be right for
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Fudan University 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT05007093
What this trial is testing

Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib

Who this might be right for
DTC - Differentiated Thyroid Cancer
Yansong Lin 20
Not applicableUnknownNCT06154863
What this trial is testing

Recurrence in Patients With Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Assiut University 100
Testing effectiveness (Phase 2)Study completedNCT02614495
What this trial is testing

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Who this might be right for
Thyroid Carcinoma
Hutchison Medipharma Limited 66
Not applicableApproved For MarketingNCT03533361
What this trial is testing

Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil

Who this might be right for
Thyroid Cancer
Eisai Inc.
Not applicableUnknownNCT04857086
What this trial is testing

The Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China

Who this might be right for
Differentiated Thyroid Cancer
Huazhong University of Science and Technology 1,400
Large-scale testing (Phase 3)UnknownNCT02586337
What this trial is testing

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Who this might be right for
Differentiated Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 113
Testing effectiveness (Phase 2)Study completedNCT01182285
What this trial is testing

A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin

Who this might be right for
Thyroid Neoplasm
National Cancer Institute (NCI) 13
Large-scale testing (Phase 3)Looking for participantsNCT06475989
What this trial is testing

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Who this might be right for
Refractory Differentiated Thyroid Gland Carcinoma
ECOG-ACRIN Cancer Research Group 264
Not applicableNot Yet RecruitingNCT07056218
What this trial is testing

Outcome of RAI131 Therapy in Patients With Differentiated Thyroid Cancer (Low and Intermediate Risk)

Who this might be right for
Thyroid Cancer
Sohag University 50
Not applicableStudy completedNCT07652450
What this trial is testing

Incidental Thyroid Cancer in Cases With Inflammatory Thyroid Lesion

Who this might be right for
Papillary Thyroid CancerHashimoto DiseaseHashimoto's Thyroiditis+1 more
Minia University 98
Testing effectiveness (Phase 2)UnknownNCT02041260
What this trial is testing

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Who this might be right for
Differentiated Thyroid Cancer (DTC)Poorly Differentiated Thyroid Cancer
Thomas Jefferson University 43
Next Page